Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases

Expert Review of Vaccines

Volumn 15, Issue 3, 2016, Pages 367-387

  Rachel Skinner, S ^a,b   Apter, Dan ^c   De Carvalho, Newton ^d   Harper, Diane M ^e,f   Konno, Ryo ^g   Paavonen, Jorma ^h   Romanowski, Barbara ⁱ   Roteli Martins, Cecilia ^j   Burlet, Nansa ^k   Mihalyi, Attila ^k   Struyf, Frank ^k  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c Vaestoliitto   (Finland)

^d PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

^f University of Louisville School of Medicine   (United States)

^g JICHI MEDICAL UNIVERSITY   (Japan)

^h UNIVERSITY OF HELSINKI   (Finland)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j LHospital Leonor M de Barros   (Brazil)

^k GSK   (Belgium)

more..

Author keywords

Cervical cancer; efficacy; HPV; human papillomavirus; literature review; randomized controlled trial; vaccination

Indexed keywords

WART VIRUS VACCINE; ALUMINUM HYDROXIDE; ASO4 MIXTURE; IMMUNOLOGICAL ADJUVANT; LIPID A;

ANUS DISEASE; CERVICAL INFECTION; COHORT ANALYSIS; CONDYLOMA ACUMINATUM; CROSS PROTECTION; DRUG EFFICACY; FEMALE; GROUPS BY AGE; HUMAN; MOUTH INFECTION; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DISEASE; VULVA DISEASE; ANALOGS AND DERIVATIVES; ANUS NEOPLASMS; COMPLICATION; CONDYLOMATA ACUMINATA; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOLOGY; MOUTH NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); UTERINE CERVICAL NEOPLASMS;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANUS NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CONDYLOMATA ACUMINATA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; LIPID A; MOUTH NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UTERINE CERVICAL NEOPLASMS;

EID: 84975744340     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1124763     Document Type: Review

References (88)

1. International Agency for Research on Cancer. Cervical cancer. Estimated incidence, mortality and prevalence worldwide in 2012, 2014 [cited 2014 Nov 16]. Available from: http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx
2. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol. 2004; 191: 114-120.
3. Brown RE, Breugelmans JG, Theodoratou D, et al. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin. 2006; 22: 663-670.
4. Annemans L, Remy V, Lamure E, et al. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium. J Med Econ. 2008; 11: 135-150.
5. Low JJ, Ko Y, Ilancheran A, et al. Health and economic burden of HPV-related diseases in Singapore. Asian Pac J Cancer Prev. 2012; 13: 305-308.
6. Salo H, Leino T, Kilpi T, et al. The burden and costs of prevention and management of genital disease caused by HPV in women: a population-based registry study in Finland. Int J Cancer. 2013; 133: 1459-1469.
7. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-19.
8. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens. Part B: biological agents. Lancet Oncol. 2009; 10: 321-322.
9. De Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11: 1048-1056.
10. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005; 191: 182-192.
11. Moscicki AB. HPV infections in adolescents. Dis Markers. 2007; 23: 229-234.
12. Collins S, Mazloomzadeh S, Winter H, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG. 2002; 109: 96-98.
13. Trottier H, Ferreira S, Thomann P, et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res. 2010; 70: 8569-8577.
14. Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis. 2004; 190: 2077-2087.
15. Insinga RP, Perez G, Wheeler CM, et al. Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev. 2010; 19: 1585-1594.
16. Koshiol J, Lindsay L, Pimenta JM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008; 168: 123-137.
17. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 1994; 169: 235-240.
18. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004; 364: 1757-1765.
19. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367: 1247-1255.
20. Romanowski B, De Borba PC, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009; 374: 1975-1985.
21. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine. 2010; 28: 6247-6255.
22. Roteli-Martins CM, Naud P, De Borba P, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother. 2012; 8: 390-397.
23. Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014; 10: 2147-2162.
24. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369: 2161-2170.
25. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374: 301-314.
26. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012; 13: 89-99.
27. Wheeler CM, Castellsague X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012; 13: 100-110.
28. Szarewski A, Poppe WA, Skinner SR, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer. 2012; 131: 106-116.
29. Szarewski A, Skinner SR, Garland SM, et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis. 2013; 208: 1391-1396.
30. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007; 298: 743-753.
31. Herrero R, Wacholder S, Rodriguez AC, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov. 2011; 1: 408-419.
32. Hildesheim A, Wacholder S, Catteau G, et al. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine. 2014; 32: 5087-5097.
33. Lang Kuhs KA, Porras C, Schiller JT, et al. Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. Am J Epidemiol. 2014; 180: 599-607.
34. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Nat Cancer Inst. 2011; 103: 1444-1451.
35. Lang Kuhs KA, Gonzalez P, Rodriguez AC, et al. Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica vaccine trial. J Infect Dis. 2014; 210: 1890-1899.
36. Kreimer AR, Gonzalez P, Katki HA, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica vaccine trial. Lancet Oncol. 2011; 12: 862-870.
37. Herrero R, Quint W, Hildesheim A, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PloS One. 2013; 8: e68329.
38. Konno R, Tamura S, Dobbelaere K, et al. Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized, controlled trial. Int J Gynecol Cancer. 2010; 20: 404-410.
39. Konno R, Tamura S, Dobbelaere K, et al. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial. Int J Gynecol Cancer. 2010; 20: 847-855.
40. Konno R, Yoshikawa H, Okutani M, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women: open follow-up of a randomized clinical trial up to 4 years post-vaccination. Hum Vaccin Immunother. 2014; 10: 1781-1794.
41. Zhu FC, Chen W, Ym H, et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial. Int J Cancer. 2014; 135: 2612-2622.
42. Skinner SR, Szarewski A, Romanowski B, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014; 384: 2213-2227.
43. Apter D, Wheeler CM, Paavonen J, et al. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clin Vaccine Immunol. 2015; 22: 361-373.
44. Struyf F, Colau B, Wheeler CM, et al. Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA. Clin Vaccine Immunol. 2015; 22: 235-244.
45. Miltz A, Price H, Shahmanesh M, et al. Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure. PloS One. 2014; 9: e90348.
46. La Torre G, De Waure C, Chiaradia G, et al. HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis. Vaccine. 2007; 25: 8352-8358.
47. Malagon T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12: 781-789.
48. Medeiros LR, Rosa DD, Da Rosa MI, et al. Efficacy of human papillomavirus vaccines: a systematic quantitative review. Int J Gynecol Cancer. 2009; 19: 1166-1176.
49. Rodriguez AC, Solomon D, Herrero R, et al. Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment. Am J Epidemiol. 2013; 178: 752-760.
50. Kreimer A, Struyf F, Del Rosario-Raymundo MR, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol. 2015 [cited 2015 Jun 9]. DOI: 10.1016/S1470-2045(15)00047-9.
51. Van Doorn LJ, Molijn A, Kleter B, et al. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol. 2006; 44: 32-38.
52. Van Alewijk D, Kleter B, Vent M, et al. A human papilloma virus testing algorithm comprising a combination of the L1 broad-spectrum SPF10 PCR assay and a novel E6 high-risk multiplex type-specific genotyping PCR assay. J Clin Microbiol. 2013; 51: 1171-1178.
53. Wheeler CM, Hunt WC, Joste NE, et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Nat Cancer Inst. 2009; 101: 475-487.
54. Pirog EC, Lloveras B, Molijn A, et al. HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Mod Pathol. 2014; 27: 1559-1567.
55. Bray F, Carstensen B, Moller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev. 2005; 14: 2191-2199.
56. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005; 337: 76-84.
57. Castanon A, Landy R, Brocklehurst P, et al. Risk of preterm delivery with increasing depth of excision for cervical intraepithelial neoplasia in England: nested case-control study. BMJ. 2014; 349: g6223.
58. Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008; 337: a1284.
59. Boxus M, Lockman L, Fochesato M, et al. Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule. Vaccine. 2014; 32: 3232-3236.
60. Romanowski B, Schwarz TF, Ferguson LM, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccin Immunother. 2014; 10: 1155-1165.
61. Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila). 2013; 6: 1242-1250.
62. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013; 309: 1793-1802.
63. World Health Organization. Immunization, vaccines and biologicals. Summary of the SAGE April 2014 meeting. [cited 2014 Nov 16]. Available from: http://www.who.int/immunization/sage/meetings/2014/april/report-summary-april-2014/en/
64. Jit M, Chapman R, Hughes O, et al. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ. 2011; 343: d5775.
65. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008; 337: a769.
66. Vaccines and Related Biological Products Advisory Committee (VRBPAC). Cervarix. Human papillomavirus Bivalent (types 16 and 18) vaccine, recombinant. Briefing document, 2009 Sep 9. [cited 2015 Sep 15]. Available from: http://www.fda.gov/downloads/Adviso.uctsAdvisoryCommittee/UCM181371.pdf
67. Di Mario S, Basevi V, Lopalco PL, et al. Are the two human papillomavirus vaccines really similar? A systematic review of available evidence: efficacy of the two vaccines against HPV. J Immunol Res. 2015; 435141. DOI: 10.1155/2015/435141.
68. World Health Organization. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014; 89: 465-492.
69. Cuzick J. Gardasil 9 joins the fight against cervix cancer. Expert Rev Vaccines. 2015 [cited 2015 May 31]. DOI: 10.1586/14760584.2015.1051470.
70. Bosch FX, De Sanjosé S, Castellsagué X. The prospects of HPV vaccination in cervical cancer prevention: results of a new independent trial. Cancer Discov. 2011; 1: 377-380.
71. GlaxoSmithKline. Clinical Study Register. Study ID: 580299/007. 2014 [cited 2015 Jun 20]. Available from: www.gsk-clinicalstudyregister.com/study/580299/007#rs
72. GlaxoSmithKline. Clinical Study Register. Study ID: 109616 (Y7). 2014 [cited 2015 Jun 20]. Available from: http://www.gsk-clinicalstudyregister.com/study/109616%20(Y7)#rs
73. Moscicki AB, Harper DM, Naud P, et al. HPV-16/18 AS04-adjuvanted vaccine: sustained immunogenicity against HPV-31 and HPV-45 non-vaccine oncogenic types up to 9.4 years. Presented at the 30th International Papillomavirus Conference and Public Health Workshops (HPV 2015); 2015 Sep 17-21; Lisbon, Portugal.
74. Lowy DR, Herrero R, Hildesheim A. Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. Lancet Oncol. 2015; 16: e226-e233.
75. Kemp TJ, Safaeian M, Hildesheim A, et al. Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(R). Vaccine. 2012; 31: 165-170.
76. Moscicki AB, Wheeler CM, Romanowski B, et al. Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women. Vaccine. 2012; 31: 234-241.
77. Van Kriekinge G, Castellsague X, Cibula D, et al. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths. Vaccine. 2014; 32: 733-739.
78. Mesher D, Soldan K, Howell-Jones R, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine. 2013; 32: 26-32.
79. Kavanagh K, Pollock KG, Potts A, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 2014; 110: 2804-2811.
80. Pollock KG, Kavanagh K, Potts A, et al. Reduction of low-and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer. 2014; 111: 1824-1830.
81. Public Health England. Declines in genital warts since start of the HPV immunisation programme. Health Protect Rep-Wkly Rep. 2014 [cited 2015 Sep 15]; 9 (22). Available from: https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/441554/hpr2215.pdf
82. Turner HC, Baussano I, Garnett GP. Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine. PloS One. 2013; 8: e75552.
83. World Health Organization. Evidence based recommendations on human papilloma virus (HPV) vaccines schedules. Background paper for SAGE discussions. 2014 [cited 2014 Nov 16]. Available from: http://www.who.int/immunization/sage/meetings/2014/april/1-HPV-Evidence-based-recommendationsWHO-with-Appendices2-3.pdf
84. Brotherton JM. Could one dose of bivalent HPV vaccine prevent cervical cancer? Lancet Oncol. 2015 [cited 2015 Jun 10]. DOI: 10.1016/S1470-2045(15)00046-7.
85. Gonzalez P, Hildesheim A, Herrero R, et al. Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. Vaccine. 2015; 33: 2141-2151.
86. Goldie SJ, Levin C, Mosqueira-Lovon NR, et al. Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru. Rev Panam Salud Publica. 2012; 32: 426-434.
87. Burger EA, Sy S, Nygard M, et al. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys. PloS One. 2014; 9: e89974.
88. Lehtinen M, Apter D, Baussano I, et al. Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial. Vaccine. 2015; 33: 1284-1290.